Biofrontera's third quarter split cleanly in two: the company won nearly every regulatory and legal battle it needed to, while its financial position weakened. The company reported a loss of $0.42 per share on revenue of $9.07 million. Earnings improved 28.8% year over year and revenue grew 29.8%. No consensus estimate was available for comparison. On the surface, a 30% top-line gain and a narrower per-share loss look like progress. Underneath, the quarter shows a business whose organic growth slowed, whose margins slipped, and whose balance sheet now depends on outside capital. That is the central tension.
The quality of the growth deserves scrutiny. Biofrontera said Ameluz unit volume rose 23.3%, with tubes reaching 25,120 versus 20,380. Customers accelerated orders in early July ahead of the ITC exclusion order on the RhodoLED XL lamp, which took effect July 6. The press release calls that pull-forward only a partial driver and credits commercial execution as well. On the call, however, management attributed substantially all of the volume growth to roughly $1.6 million of orders pulled forward. The underlying order data support the more cautious reading: order growth slowed to 6% year over year from 18.6% in the first half.
The per-share improvement also overstates the progress. Net loss narrowed only modestly, to $6.4 million from $6.6 million. Weighted-average shares rose to 15.3 million from 10.8 million, so dilution did much of the work in shrinking the loss per share.
Margins moved the wrong way sequentially. Gross margin of 74.4% beat the 70.7% of a year ago, thanks to the lower Ameluz cost structure from the October 2025 Strategic Transaction. It fell short, though, of the roughly 80% posted in each of the first two quarters. The shortfall came from higher lamp costs and $0.3 million of ITC-related inventory write-downs. Management guided fourth-quarter gross margin back to about 80%.
The bigger swing was in operating costs. SG&A jumped to $12.5 million from $9.7 million in the second quarter. The increase reflected $0.9 million of higher ITC legal fees plus manufacturing and regulatory functions the company has taken in-house. As a result, adjusted EBITDA fell to -$5.5 million from just -$0.2 million in the second quarter. That reversal erased much of the operating leverage investors saw earlier in the year.
The strategic news was genuinely strong. The FDA approved Ameluz for superficial basal cell carcinoma on September 9, ahead of the September 28 PDUFA date. Ameluz with red light is now the first PDT approved in the U.S. for a cancerous skin tumor. Five days later, Customs and Border Protection ruled that the redesigned XL-C lamp falls outside the exclusion order. The share of Ameluz volume affected by the ITC matter has fallen from about 25% to about 10%. Customer ordering returned to year-ago levels by September, and remediation should be substantially complete by the end of the second quarter of 2027.
The pipeline also advanced. An sNDA extending the actinic keratosis label to the extremities, neck and trunk carries an August 5, 2027 PDUFA date. The sBCC launch begins with a mid-January launch meeting and a full launch in the first quarter. That launch can run through an installed base of 853 lamps across 742 offices, and new purchasing locations rose 39%. Management also plans Federal Circuit appeals against both the ITC determination and the USPTO Director decision.
The balance sheet is where bears have legitimate ammunition. Cash fell to $3.2 million from $4.7 million in the second quarter and $6.3 million in the first. Stockholders' equity swung to a $0.2 million deficit, so the company no longer meets Nasdaq's minimum equity requirement. The going-concern doubt was reiterated, and the mitigation plan now explicitly includes possible equity or debt raises. The 2026 cash-flow-breakeven goal, affirmed on the prior two calls, was not repeated. A $1.0 million Xepi milestone expected in December depends on the buyer's performance, and $4.7 million of convertible notes mature in November 2027. Nine-month operating cash burn of $3.2 million, down from $11.0 million, is real improvement, but it leaves little cushion.
The market has already priced in much of this concern. Shares hit a 52-week high of $1.66 on September 8, the day before the sBCC approval. They then gave back the entire move and now sit near $0.93. That is 44% below the peak, 27.1% below the open after the prior report, and about 10% below the 200-day moving average. The stock has bounced about 19% off its October 23 low of $0.78. Price and AVWAP trend readings remain negative. Investor sentiment was roughly unchanged and still negative, edging to -0.33 from -0.31, so the regulatory wins did little to change expectations.
The bottom line is that Biofrontera now has the label, the lamp, and the commercial footprint it needed, but not the financial runway to exploit them comfortably. The 30% revenue growth was largely borrowed from the fourth quarter, and adjusted EBITDA deteriorated sharply from the second quarter. With dilution likely, investors must weigh a credible 2027 launch story against near-term financing risk.